Skip header and navigation

1 records – page 1 of 1.

A biologic pharmacosurveillance program for rheumatoid arthritis: a single-center experience.

https://arctichealth.org/en/permalink/ahliterature116627
Source
Clin Rheumatol. 2013 Jun;32(6):875-7
Publication Type
Article
Date
Jun-2013
Author
Anthony S Russell
Catherine Mallon
Barbara Conner-Spady
Walter Maksymowych
Author Affiliation
University of Alberta, Edmonton, Alberta T6G2S2, Canada. as.russell@ualberta.ca
Source
Clin Rheumatol. 2013 Jun;32(6):875-7
Date
Jun-2013
Language
English
Publication Type
Article
Keywords
Adrenal Cortex Hormones - administration & dosage
Alberta
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - therapy
Databases, Factual
Female
Humans
Isoxazoles - administration & dosage
Male
Methotrexate - administration & dosage
Middle Aged
Product Surveillance, Postmarketing - methods
Registries
Remission Induction
Severity of Illness Index
Abstract
We have reviewed the experience in a single center of a biologic register for rheumatoid arthritis patients. Over the past decade, the entry demographics show that we are treating patients at an earlier stage and with slightly less severe disease. Our outcomes measured by the percentage in DAS28 remission are comparable with national databases. We were surprised by the small number who were switched from their first biologic to a second (27 %), but this might reflect the lack of a firm "treat to target" approach. Our use of concomitant methotrexate/leflunomide is less than we would have liked and thought, but our use of concomitant corticosteroids is much less than normally seen. A single-center registry can provide useful monitoring and quality assurance data and stimulate change.
PubMed ID
23377198 View in PubMed
Less detail